Virus-like particle vaccines
Vaccines are among the most successful and cost-effective public health tools for preventing infectious diseases and death. Virus-like particles (VLPs) have made impressive progress in the field of vaccinology over the last three decades so that several VLP-based vaccines are commercially available...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Book section |
| Language: | English |
| Published: |
Academic Press
2022
|
| _version_ | 1826310656088866816 |
|---|---|
| author | Mukhopadhyay, E Hill, AVS Salman, AM |
| author2 | Ashfield, R |
| author_facet | Ashfield, R Mukhopadhyay, E Hill, AVS Salman, AM |
| author_sort | Mukhopadhyay, E |
| collection | OXFORD |
| description | Vaccines are among the most successful and cost-effective public health tools for preventing infectious diseases and death. Virus-like particles (VLPs) have made impressive progress in the field of vaccinology over the last three decades so that several VLP-based vaccines are commercially available and generating great public health impact, for example, the hepatitis B virus and the human papillomavirus (HPV) vaccines or in advanced clinical trials such as the RTS,S and R21 VLP malaria vaccines. We have growing in-house experience in Oxford of the use of a wide range of VLPs to target malaria and other diseases by vaccination. As VLPs lack genetic material, they have no replication capacity and are considered very safe. Additionally, VLP-based vaccines have significant ability to induce both innate and adaptive immune responses as well as being safe templates with favorable low-cost and large-scale manufacturing available. |
| first_indexed | 2024-03-07T07:56:40Z |
| format | Book section |
| id | oxford-uuid:dab1b59f-a1b5-4145-ba6e-f382e284a35b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:56:40Z |
| publishDate | 2022 |
| publisher | Academic Press |
| record_format | dspace |
| spelling | oxford-uuid:dab1b59f-a1b5-4145-ba6e-f382e284a35b2023-08-16T17:08:31ZVirus-like particle vaccinesBook sectionhttp://purl.org/coar/resource_type/c_1843uuid:dab1b59f-a1b5-4145-ba6e-f382e284a35bEnglishSymplectic ElementsAcademic Press2022Mukhopadhyay, EHill, AVSSalman, AMAshfield, ROli, ANEsimone, CAnagu, LVaccines are among the most successful and cost-effective public health tools for preventing infectious diseases and death. Virus-like particles (VLPs) have made impressive progress in the field of vaccinology over the last three decades so that several VLP-based vaccines are commercially available and generating great public health impact, for example, the hepatitis B virus and the human papillomavirus (HPV) vaccines or in advanced clinical trials such as the RTS,S and R21 VLP malaria vaccines. We have growing in-house experience in Oxford of the use of a wide range of VLPs to target malaria and other diseases by vaccination. As VLPs lack genetic material, they have no replication capacity and are considered very safe. Additionally, VLP-based vaccines have significant ability to induce both innate and adaptive immune responses as well as being safe templates with favorable low-cost and large-scale manufacturing available. |
| spellingShingle | Mukhopadhyay, E Hill, AVS Salman, AM Virus-like particle vaccines |
| title | Virus-like particle vaccines |
| title_full | Virus-like particle vaccines |
| title_fullStr | Virus-like particle vaccines |
| title_full_unstemmed | Virus-like particle vaccines |
| title_short | Virus-like particle vaccines |
| title_sort | virus like particle vaccines |
| work_keys_str_mv | AT mukhopadhyaye viruslikeparticlevaccines AT hillavs viruslikeparticlevaccines AT salmanam viruslikeparticlevaccines |